An Open, Randomised, Single Dose, 2-period, 2-sequence Crossover Adhesion Study of Two Different Transdermal Patches Containing Rotigotine.

PHASE1TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 3, 2019

Primary Completion Date

March 16, 2020

Study Completion Date

March 16, 2020

Conditions

Parkinson Disease

Interventions

DRUG

Rotigotine TTS (Test)

Transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24.

DRUG

Neupro (Reference)

Neupro®: transdermal patch containing Rotigotine 18 mg to deliver 8 mg/24 h.

Trial Locations (1)

Sandoz Investigative Site, Hamburg